You are visiting a website that is not intended for your region

The page or information you have requested is intended for an audience outside the United States. By continuing to browse you confirm that you are a non-US resident requesting access to this page or information.

Switch to the US site

This website uses cookies

By continuing to use this website you consent to using cookies. For more information about cookies and how we use them, please see our Privacy Policy.

New insights in dialysis access

Globally, more than 2 million people are receiving dialysis treatment or awaiting a kidney transplant. For these dialysis patients, treatment falls into three kinds of access: fistula, grafts and catheters (central venous catheter).

Why some physicians are saying "Catheter Last"

The "Fistula First Initiative" remains the gold standard of care around the world. However, this recommendation is not suitable for all patients; operators turn to central venous catheters (CVCs) second and synthetic grafts last. Publications have shown an increase in severe complications associated with CVCs, resulting in a paradigm shift to "Fistula First, Catheter Last." Grafts capable of early cannulation are a viable option for avoiding catheter-related complications.

Learn why grafts are a great 1st or 2nd option for early cannulation

An early cannulation option that is not a central venous catheter (CVC)

Sometimes fistula is not an option. Skilled operators need a prosthesis designed to withstand repeated needle cannulation, without the complications traditionally associated with conventional ePTFE grafts. Traditional ePTFE graft sweating, pseudoaneurysm, and two to four week maturation times on cannulation are the reason why many operators turn to CVC catheters. Unlike traditional grafts, publications demonstrate that Flixene can be cannulated in 24-72 hours while maintaining comparable patency rates to ePTFE grafts which were given 2-4 weeks for maturation.  Combined with Getinge’s proprietary Graft Deployment System (GDS), Flixene is changing patient care around the globe.

Read more about early cannulation

Optimal techniques for arteriovenous access cannulation

Proper site maintenance and access procedures are essential to maintaining patency and giving our patients the level of service they need.  Are you practicing the correct techniques for determining the access site, preparation, needle placement and blood flow?  What are the signs that your patient is doing well or needs help?

Follow the Ask, Look, Listen method and the KDOQI guidelines

Published data on an ePTFE graft that allows upper arm cannulation in days, not weeks

The study compares the clinical outcomes of 108 patients who have received one of the following three upper arm access types; transposed brachiobasilic arteriovenous fistula (BBAVF), autogenous brachial vein-brachial artery access (ABBA), and Flixene ePTFE vascular graft (AVG). While BBAVF remains the ideal standard of care for most patients, authors noted comparable overall results for AVG patients and improved outcomes for select patients who received AVGs.

Read more about upper arm access using an ePTFE graft